Qimono Qimo Male

Qimo male is a disinfectable closed needle-free safety connector.

Qimo male is a disinfectable closed needle-free safety connector. It is a safety captive adaptor for male Luer-lock hubs.Once attached, it cannot be disconnected. It connects only to Qimo female .

Vygon Code: N/A

About Product

Qimono the complete closed system for safe delivery of cytotoxic drugs

Stay safe with Qimono

It is widely documented that exposure to Systemic Anti-Cancer Therapy (SACT), can pose a significant health risk to patients during treatment as well as healthcare workers involved in the preparation and administration of the drugs .

Many SACT agents are known to be carcinogenic, teratogenic and mutagenic. Exposure may be through skin contact, skin absorption, inhalation of aerosols and drug particles as well as ingestion and needlestick injuries. This can occur at various points of the treatment process: during the preparation of the medication, whilst the drugs are administered and after therapy .

Adverse health effects reported by chemotherapy nurses include headaches, dizziness, nausea and hair loss.

Description of the device

Qimo Male is a multi-purpose, closed, needle-free, I.V. connection device which has been designed for the preparation and safe administration of hazardous drugs. Qimo Male has a very easily disinfectable membrane (disinfection must be carried out before and after use) which automatically closes when Qimo Female is disconnected.

Qimo Male is a safety adaptor, the proximal end of which must be connected onto the male Luer-lock end of a syringe, an extension tube or an infusion set.
At the distal end, the Luer bayonet end can only be connected to devices which feature a Qimo Female end.
Note: after the connection of Qimo Male onto a Luer-lock male hub, Qimo Male rotates and cannot be disconnected anymore.

Qimo Male can only be connected to the female Luer bayonet end of Qimo Female, by placing the lugs of Qimo Male into the notches of the bayonet ring of Qimo Female.
During the connection, the internal metallic tube of Qimo Female opens both the membranes of Qimo Female and of Qimo Male and the two conduits fit in together.
It is then possible to inject, infuse or withdraw samples of drugs.
During the disconnection, the membranes automatically close, which ensures the sealing of both devices.

Maximum number of connection: 10
Priming volume: 0.35 ml

Qimo Male is lipid-resistant.

Code 7210.91: Qimo Male – 1 unit in a supple blister.
Code 7210.910: Set of 25 Qimo Male : – 25 units in a blister / 100 units in a box / 1 800 units in a case

To secure syringes used for medication preparation.

Composition of the device [description]
Components in contact with the solution:
– Internal conduit in PBT and membrane in silicone
– Safety lock in polypropylene
– Lubricant silicone

Qimo Male is a needleless, disinfectable closed I.V. system.Qimo Male is a safety adaptor mounted on syringe, an infusion set or an extension tube which can only be connected onto a device featuring a Qimo Female end.

UOI Units: Box

Contains Latex: No

Contains DEHP: No

Pyrogen Free: Yes

Sterile Medical Device: Yes

Product Support

Vygon is committed to education and support for our customers. We provide in-service training sessions for all staff and all shift patterns, to help ensure your clinicians achieve best practice when delivering care to patients. In addition, patient advice leaflets and children’s bravery certicates are available on request, to help assist the clinicians in supporting and informing their patients.

Supporting Documents Download:

Contact Us

Events

There are currently no related events to this product.

Related Products

News

NIOSH Testing Success for Vygon’s CSTD Qimono

Tests to evaluate the effectiveness of closed system transfer devices (CSTD) in preventing exposure to dangerous chemotherapy drugs, has proven Vygon’s Qimono exceeds the rigorous NIOSH standards.

Read More

USP 800: A new standard of safety for US nurses

From 1st December this year American nurses handling hazardous drugs whilst treating cancer patients are legally protected by new standards covered by USP 800 guidelines.

Read More

Sact Safety Campaign Update

SACT Safety Campaign Update November 22nd 2019 Three years on from presenting their initial work into the safety risks facing …

Read More